BACKGROUND: Effective and safe products are needed for long-term management of scalp psoriasis. This study investigated the long-term safety and efficacy of a two-compound formulation (calcipotriol 50 microg/g plusbetamethasone dipropionate 0.5 mg/g) for scalp psoriasis. METHODS: In this 52-week, international, double-blind study, 869 patients with moderate-to-severe scalp psoriasis were randomized to either a two-compound scalp formulation (n = 429) or calcipotriol (n = 440). RESULTS:Adverse drug reactions were less frequent in the two-compound group compared with the calcipotriol group (17.2 vs. 29.5%; p < 0.001). Incidences of adverse events possibly associated with long-term corticosteroid use were low in both the two-compound (2.6%) and the calcipotriol (3.0%) groups. Disease was satisfactorily controlled in 92.3% of visits in the two-compound group versus 80.0% in the calcipotriol group (p < 0.001). CONCLUSION: The two-compound scalp formulation demonstrated a high level of safety and efficacy in long-term management of scalp psoriasis. 2008 S. Karger AG, Basel.
RCT Entities:
BACKGROUND: Effective and safe products are needed for long-term management of scalp psoriasis. This study investigated the long-term safety and efficacy of a two-compound formulation (calcipotriol 50 microg/g plus betamethasone dipropionate 0.5 mg/g) for scalp psoriasis. METHODS: In this 52-week, international, double-blind study, 869 patients with moderate-to-severe scalp psoriasis were randomized to either a two-compound scalp formulation (n = 429) or calcipotriol (n = 440). RESULTS: Adverse drug reactions were less frequent in the two-compound group compared with the calcipotriol group (17.2 vs. 29.5%; p < 0.001). Incidences of adverse events possibly associated with long-term corticosteroid use were low in both the two-compound (2.6%) and the calcipotriol (3.0%) groups. Disease was satisfactorily controlled in 92.3% of visits in the two-compound group versus 80.0% in the calcipotriol group (p < 0.001). CONCLUSION: The two-compound scalp formulation demonstrated a high level of safety and efficacy in long-term management of scalp psoriasis. 2008 S. Karger AG, Basel.
Authors: K Kragballe; L Barnes; K J Hamberg; P Hutchinson; F Murphy; S Møller; T Ruzicka; P C Van De Kerkhof Journal: Br J Dermatol Date: 1998-10 Impact factor: 9.302
Authors: Christopher E M Griffiths; Andrew Y Finlay; Colin J Fleming; Jonathan N W N Barker; Fabienne Mizzi; Stéphanie Arsonnaud Journal: J Dermatolog Treat Date: 2006 Impact factor: 3.359
Authors: K Kragballe; J Austad; L Barnes; A Bibby; M de la Brassinne; F Cambazard; C Fleming; H Heikkilä; D Jolliffe; J Peyri; A Svensson; J Toole; G Wozel Journal: Br J Dermatol Date: 2006-06 Impact factor: 9.302
Authors: John Koo; Stephen Tyring; William P Werschler; Suzanne Bruce; Martin Olesen; John Villumsen; Jerry Bagel Journal: J Dermatolog Treat Date: 2015-10-07 Impact factor: 3.359